Welcome to our dedicated page for BOSTON SCIENTIFIC SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BOSTON SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BOSTON SCIENTIFIC's regulatory disclosures and financial reporting.
Boston Scientific director Edward J. Ludwig received an annual equity award in the form of restricted stock. On the grant date, he acquired 3,800 shares of common stock at no cash cost as a grant or award. The award reflects a value of $215,000 divided by the closing price of the common stock on the grant date. These restricted shares vest in full at the next annual meeting of stockholders. Following this grant, Ludwig directly holds 21,779 shares of Boston Scientific common stock.
Boston Scientific Corp: FMR LLC reports beneficial ownership of 75,835,683.30 shares of Common Stock, equal to 5.1% of the class. The filing (Amendment No. 5 to Schedule 13G/A) lists sole dispositive power for 75,835,683.30 shares and sole voting power for 65,765,394.36 shares. Signature pages show authority via power of attorney and dates associated with the amendment and signatures.
Boston Scientific Corporation held its 2026 Annual Meeting of Stockholders in a virtual-only format, where stockholders approved key changes to the company’s charter and governance framework. The company’s Fourth Restated Certificate of Incorporation became effective after stockholders voted to remove supermajority voting provisions and to add exculpation protections for certain officers as permitted by Delaware law.
All 10 director nominees were elected for one-year terms, stockholders approved the advisory vote on compensation for named executive officers, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year. Stockholders also approved an amendment to the Employee Stock Purchase Plan to increase shares reserved, while two stockholder proposals related to giving shareholders the ability to call special meetings did not receive sufficient support.
Boston Scientific EVP Padraig Andrew O'Connor reported routine equity compensation activity involving restricted stock units. On May 2, 2026, he exercised awards covering 1,802 restricted stock units, receiving the same number of shares of Boston Scientific common stock.
To satisfy tax obligations related to this vesting, 872 common shares were disposed of at $56.50 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, O'Connor directly holds 7,024 shares of common stock.
BOSTON SCIENTIFIC CORP executive Arthur C. Butcher reported routine equity compensation activity. On May 2, 2026, he exercised 2,102 Restricted Stock Units, receiving the same number of common shares. These RSUs each represent a commitment to issue one share of Boston Scientific common stock.
To cover tax obligations, 1,007 common shares were disposed of through a tax-withholding transaction at $56.50 per share, which is not an open-market sale. After these transactions, he holds 56,887 common shares directly and 20,228 shares indirectly through the company’s 401(k) Retirement Savings Plan.
Boston Scientific delivered strong first-quarter 2026 results, with net sales of $5.203 billion, up 11.6% from $4.663 billion, driven by double-digit growth in Cardiovascular and MedSurg businesses. Net income attributable to common stockholders rose to $1.341 billion from $674 million, or diluted EPS of $0.90 versus $0.45.
Adjusted diluted EPS was $0.80, up 6.0%. Organic and operational net sales growth were both 9.4%, reflecting innovation and commercial execution, particularly in Electrophysiology and Interventional Cardiology & Vascular Therapies. Cash from operations was $348 million, with higher acquisition spending and capex leading to lower cash balances.
The company continued its acquisition strategy, closing the Nalu Medical deal (total preliminary consideration $588 million), completing the prior Cortex acquisition, signing to buy Scivita Medical and agreeing to acquire Penumbra for about $14.5 billion. It added new revolving credit and term loan facilities to support funding and ended the quarter with total assets of $44.351 billion, senior notes of $10.935 billion and a leverage ratio of 1.87x versus a 4.25x covenant limit.
Boston Scientific Corp disclosure: Vanguard Capital Management reports beneficial ownership of 111,127,205 shares of Common Stock, representing 7.47% of the class. The filing shows sole dispositive power over 111,127,205 shares and sole voting power over 14,715,637 shares, signed 04/29/2026.
Boston Scientific reported strong first quarter 2026 results, with net sales of $5.203 billion, up 11.6% year over year on a reported basis and 9.4% on an operational and organic basis. GAAP net income attributable to common stockholders rose to $1.341 billion, or $0.90 per diluted share, compared to $0.45 a year earlier, while adjusted EPS increased to $0.80 from $0.75, slightly above guidance.
Growth was broad-based, led by Cardiovascular net sales up 13.5% reported and 11.2% operational and organic, and MedSurg up 7.8% reported. By region, net sales grew 10.9% in the U.S., 14.7% in Asia-Pacific and 19.0% in Latin America and Canada on a reported basis.
For full year 2026, the company now expects net sales growth of 7.0–8.5% reported and 6.5–8.0% organic, and adjusted EPS of $3.34–$3.41. Second quarter 2026 guidance calls for reported net sales growth of 5.5–7.5%, organic growth of 5.0–7.0%, and adjusted EPS of $0.82–$0.84.
Penumbra, Inc. has agreed to be acquired by Boston Scientific Corporation in a cash-and-stock merger. Under the Agreement and Plan of Merger, each issued and outstanding Penumbra share (other than excluded shares) will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific shares, subject to a proration mechanism that allocates 73.26% of outstanding Penumbra shares to cash consideration and 26.74% to stock consideration.
The Special Meeting of Penumbra stockholders is scheduled for May 6, 2026 to vote on adoption of the merger agreement. Boston Scientific is expected to issue approximately 43,866,267 shares in the transaction, with former Penumbra stockholders holding about 2.87% of Boston Scientific post-close, based on figures as of March 27, 2026.